View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

ENANTA PHARMACEUTICALS sees a downgrade to Slightly Negative on accoun...

The independent financial analyst theScreener just lowered the general evaluation of ENANTA PHARMACEUTICALS (US), active in the Health Care Providers industry. As regards its fundamental valuation, the title now shows 2 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date December 3, 2021, the closing pric...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

BAC BANK OF AMERICA CORP
ANTM ANTHEM INC.
ILMN ILLUMINA INC.
CVA COVANTA HOLDING CORPORATION
DEI DOUGLAS EMMETT INC
BK BANK OF NEW YORK MELLON CORPORATION
C CITIGROUP INC.
WIRE ENCORE WIRE CORPORATION
TS TENARIS S.A. ADS
TPRE SIRIUSPOINT LTD
TFX TELEFLEX INCORPORATED
SU. SUNCOR ENERGY INC.
SJI SOUTH JERSEY INDUSTRIES INC.
SIGI SELECTIVE INSURANCE GROUP INC.
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
SFNC SIMMONS FIRST NATIONAL CORPORATION CLASS A
SCHL SCHOLASTIC CORPORATION
SBNY SIGNATURE BANK
RNST RENASANT CORPORATION
PSB PS BUSINESS PARKS INC.
PPC PILGRIM'S PRIDE CORPORATION
OFC CORPORATE OFFICE PROPERTIES TRUST
NWE NORTHWESTERN CORPORATION
NTCT NETSCOUT SYSTEMS INC.
MO ALTRIA GROUP INC
MEI METHODE ELECTRONICS INC.
LGND LIGAND PHARMACEUTICALS INCORPORATED
JWN NORDSTROM INC.
IPAR INTER PARFUMS INC.
INDB INDEPENDENT BANK CORP.
IDA IDACORP INC.
PU6D HSBC HOLDINGS (ADR)
HMSY HMS HOLDINGS CORP.
HIG HARTFORD FINANCIAL SERVICES GROUP INC.
GNTX GENTEX CORPORATION
GLN GLATFELTER CORPORATION
FRT FEDERAL REALTY INVESTMENT TRUST
FRME FIRST MERCHANTS CORPORATION
EOG EOG RESOURCES INC.
ENTA ENANTA PHARMACEUTICALS INC.
EGBN EAGLE BANCORP INC.
CVBF CVB FINANCIAL CORP.
CRS CARPENTER TECHNOLOGY CORPORATION
CR CRANE CO.
COHR COHERENT INC.
CATY CATHAY GENERAL BANCORP
BP BP PLC ADS
KRNY KEARNY FINANCIAL CORP.
UVE UNIVERSAL INSURANCE HOLDINGS INC.
NPWA SMITH & NEPHEW PLC
BRC BRADY CORPORATION CLASS A
DRQ DRIL-QUIP INC.
KALU KAISER ALUMINUM CORPORATION
TAP MOLSON COORS BEVERAGE COMPANY CLASS B
THG HANOVER INSURANCE GROUP INC.
HNW PIONEER DIVERSIFIED HIGH INCOME TRUST
SWM SCHWEITZER-MAUDUIT INTERNATIONAL INC.
TR TOOTSIE ROLL INDUSTRIES INC.
STBA S&T BANCORP INC.
HOPE HOPE BANCORP INC.
ATGE ADTALEM GLOBAL EDUCATION INC.
BXS BANCORPSOUTH BANK
BKNG BOOKING HOLDINGS INC.
CI CIGNA CORPORATION
TCF TCF FINANCIAL CORPORATION
Valens Research
  • Valens Research

UAFRS vs As Reported Monthly Highlights - 2020 06 30

This month, Valens identified distortions and the corresponding adjustments to correct for those distortions for GM, RNG, DG, MMI, ENTA and JILL.

Valens Research
  • Valens Research

UAFRS vs As Reported Weekly Highlights - 2020 06 04

This week, Valens identified distortions and the corresponding adjustments to correct for those distortions for ENTA, DOV, and TRUE.

Valens Research
  • Valens Research

Valens Equity Insights and Inflections - 2020 04 07

TTD currently trades above corporate averages relative to UAFRS-based (Uniform) earnings, with a 35.7x Uniform P/E. However, even at these levels, the market is pricing in expectations for Uniform ROA to collapse from 31% in 2019 to 6% in 2024, accompanied by 62% Uniform asset growth going forward. Meanwhile, analysts have similar expectations, projecting Uniform ROA to fade to 20% by 2021, accompanied by 28% Uniform asset growth. That said, management is confident about their consistent EBITDA ...

Valens Research
  • Valens Research

ENTA - Embedded Expectations Analysis - 2020 04 03

 Enanta Pharmaceuticals, Inc. (ENTA:USA) currently trades below historical averages relative to UAFRS-based (Uniform) assets, with a 1.4x Uniform P/B. At these levels, the market has bearish expectations for the firm, and management may be concerned about their RSVP study, EDP-297, and EDP-514  Specifically, management may have concerns about the success of their RSVP study on RSV progress and symptoms and the success of EDP-938's Phase 2 study for pediatric patients. In addition, they ma...

Valens Research
  • Valens Research

Valens Equity Insights and Inflections - 2019 10 29

AXL currently trades below corporate averages relative to UAFRS-based (Uniform) Earnings, with an 11.9x Uniform P/E (Fwd V/E′). At these levels, the market is pricing in expectations for Uniform ROA to fade from 17% in 2018 to 5% in 2023, accompanied by 4% Uniform Asset growth going forward. Analysts have similar expectations, projecting Uniform ROA to fade to 10% in 2020, accompanied by 1% Uniform Asset shrinkage. Meanwhile, management is confident about their margins, sales, and cost managem...

Valens Research
  • Valens Research

ENTA - Embedded Expectations Analysis - 2019 10 25

Enanta Pharmaceuticals, Inc. (ENTA:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) Earnings, with an 18.9x Uniform P/E. At these levels, the market has bearish expectations for the firm, and management may be concerned about net income, R&D costs, and their pipeline. Specifically, management may lack confidence in their ability to initiate their first Phase IIb study for EDP-938 during 2019, and they may be concerned about the effectiveness of their EDP-514 comp...

MarketLine Department
  • MarketLine Department

Achillion Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partne...

Summary Marketline's Achillion Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Achillion Pharmaceuticals, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensiv...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • A number of Auto Component suppliers are showing signs of possible bottoms and reversals. • Offshore oil drillers continue to develop positively. Long-term trends are attractive. • The industrial Manufacturing Sector is increasingly showing positive inflections. • Communication equipment and electronic component suppliers continue to develop positively.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • Biotechs are breaking out. XBI and IBB ETF's are bullish. • Homebuilders appear to be staging near-term reversals in price and RS. • Railroads continue to lead in the Transportation Sector. Many truckers are reversing near-term downtrends. • A few Consumer Staples equities are staging price and RS reversals. (Example POST)

 PRESS RELEASE

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second...

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal second quarter ended March 31, 2018. Enanta’s results for the quarter benefited from $44 million of royalty revenue on AbbVie’s $919 million in sales of its HCV regimens that contain either of the two protease inhibitor products developed through Enanta’s collab...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch